Literature DB >> 24004671

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

Sanne J de Haart1, Niels W C J van de Donk, Monique C Minnema, Julie H Huang, Tineke Aarts-Riemens, Niels Bovenschen, Huipin Yuan, Richard W J Groen, Douglas W McMillin, Jana Jakubikova, Henk M Lokhorst, Anton C Martens, Constantine S Mitsiades, Tuna Mutis.   

Abstract

PURPOSE: Cellular immunotherapy frequently fails to induce sustained remissions in patients with multiple myeloma, indicating the ability of multiple myeloma cells to evade cellular immunity. Toward a better understanding and effective therapeutic modulation of multiple myeloma immune evasion mechanisms, we here investigated the role of the tumor microenvironment in rendering multiple myeloma cells resistant to the cytotoxic machinery of T cells. EXPERIMENTAL
DESIGN: Using a compartment-specific, bioluminescence imaging-based assay system, we measured the lysis of luciferase-transduced multiple myeloma cells by CD4(+) or CD8(+) CTLs in the presence versus absence of adherent accessory cells of the bone marrow microenvironment. We simultaneously determined the level of CTL activation by measuring the granzyme B release in culture supernatants.
RESULTS: Bone marrow stromal cells from patients with multiple myeloma and healthy individuals, as well as vascular endothelial cells, significantly inhibited the lysis of multiple myeloma cells in a cell-cell contact-dependent manner and without substantial T-cell suppression, thus showing the induction of a cell adhesion-mediated immune resistance (CAM-IR) against CTL lysis. Further analyses revealed that adhesion to accessory cells downregulated Fas and upregulated the caspase-3 inhibitor survivin in multiple myeloma cells. Reconstitution of Fas expression with bortezomib enhanced the CTL-mediated lysis of multiple myeloma cells. Repressing survivin with the small-molecule YM155 synergized with CTLs and abrogated CAM-IR in vitro and in vivo.
CONCLUSION: These results reveal the cell adhesion-mediated induction of apoptosis resistance as a novel immune escape mechanism and provide a rationale to improve the efficacy of cellular therapies by pharmacologic modulation of CAM-IR. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24004671     DOI: 10.1158/1078-0432.CCR-12-3676

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  27 in total

1.  A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Authors:  Esther Drent; Maria Themeli; Renée Poels; Regina de Jong-Korlaar; Huipin Yuan; Joost de Bruijn; Anton C M Martens; Sonja Zweegman; Niels W C J van de Donk; Richard W J Groen; Henk M Lokhorst; Tuna Mutis
Journal:  Mol Ther       Date:  2017-05-13       Impact factor: 11.454

Review 2.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

3.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Authors:  I S Nijhof; R W J Groen; H M Lokhorst; B van Kessel; A C Bloem; J van Velzen; R de Jong-Korlaar; H Yuan; W A Noort; S K Klein; A C M Martens; P Doshi; K Sasser; T Mutis; N W C J van de Donk
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

4.  Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone.

Authors:  Timothy N Trotter; Justin T Gibson; Tshering Lama Sherpa; Pramod S Gowda; Deniz Peker; Yang Yang
Journal:  Am J Pathol       Date:  2016-09-17       Impact factor: 4.307

5.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Authors:  Esther Drent; Richard W J Groen; Willy A Noort; Maria Themeli; Jeroen J Lammerts van Bueren; Paul W H I Parren; Jürgen Kuball; Zsolt Sebestyen; Huipin Yuan; Joost de Bruijn; Niels W C J van de Donk; Anton C M Martens; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

6.  Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.

Authors:  Christie P M Verkleij; Marloes E C Broekmans; Mark van Duin; Kristine A Frerichs; Rowan Kuiper; A Vera de Jonge; Martin Kaiser; Gareth Morgan; Amy Axel; Rengasamy Boominathan; Jocelyn Sendecki; Amy Wong; Raluca I Verona; Pieter Sonneveld; Sonja Zweegman; Homer C Adams; Tuna Mutis; Niels W C J van de Donk
Journal:  Blood Adv       Date:  2021-04-27

7.  Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Authors:  Leo Hansmann; Lisa Blum; Chia-Hsin Ju; Michaela Liedtke; William H Robinson; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2015-02-20       Impact factor: 11.151

Review 8.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

9.  Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Authors:  Lisa C Holthof; Hilma J van der Horst; Susan E van Hal-van Veen; Ruud W J Ruiter; Fengzhi Li; Marijke Buijze; Morten N Andersen; Huipin Yuan; Joost de Bruijn; Niels W C J van de Donk; Henk M Lokhorst; Sonja Zweegman; Richard W J Groen; Tuna Mutis
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

10.  CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.

Authors:  Arwen Stikvoort; Jort van der Schans; Subhashis Sarkar; Renée Poels; Ruud Ruiter; Jyoti Naik; Huipin Yuan; Joost D de Bruijn; Niels W C J van de Donk; Sonja Zweegman; Maria Themeli; Richard Groen; Michael O'Dwyer; Tuna Mutis
Journal:  Hemasphere       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.